At Janssen, we believe that sponsoring and supporting Continuous Professional Development (CPD) programmes (also known as Continuous Medical Education or CME) for HCPs is part of our responsibility for the medicines we develop. By increasing knowledge about diseases and the latest standards of care and treatments, we can help to enhance medical practice as well as improve patient outcomes.
Through our CPD programmes we aim to contribute to high quality education in true partnership with the medical community, to ensure that important new medical advances are discussed in a variety of settings from international congresses to smaller educational meetings.
Strict company principles ensure that this happens in an unbiased way and is transparent about our interactions with individual HCPs, as well as those with medical societies and institutions we can help to enhance medical practices.
We provide financial support in the form of grants and sponsorships to the major International, National and European learned society congresses because of the role they play in the dissemination of important medical advances.
The educational meetings we support must foster scientific exchange and disseminate latest standard of care to facilitate safe and effective treatment for patients. The Janssen policy follows the guidelines from the European Union of Medical Specialists (UEMS), the largest European accreditation body for supporting educational meetings.
At a local level, Janssen follows the national regulations in regards to events accreditation and Health Authority (HA) endorsement.
We support medical educational events and activities, which are organised with independent experts according to strict Janssen principles. The policy Janssen follows is based on the Irish Pharmaceutical Healthcare Association (IPHA) code on the promotion of prescription-only medicines and interactions with HCPs. Further information on the code is available from IPHA.
We provide support for individual HCPs to attend congresses and meetings. HCPs have a responsibility to keep up to date with medical advances through continued education, along with other pharmaceutical companies; Janssen is taking part of the responsibility here. The selection process for Janssen is transparent and based on HCP’s educational needs or active involvement in a meeting or event.
We are confident that the Janssen Way meets society’s expectations of transparent and unbiased CPD, whilst fostering scientific exchange and knowledge dissemination to ensure the best treatment outcomes for patients.
CP-229344 | April 2021